Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2012

View Archived Issues

Skuldtech and AB Science identify new markers for pancreatic cancer survival

Eisai: second quarter of fiscal 2012 in review

Avaxia Biologics presents promising in vivo results for AVX-470m

Astellas Pharma presents overview of second quarter of fiscal 2012

Promising results reported from phase IIa trial of UISH-001

Two phase III trials of Epanova meet primary and secondary endpoints

FDA approves Pfizer's Xeljanz for rheumatoid arthritis

Takeda Pharmaceutical reviews accomplishments of second quarter of fiscal 2012

GlaxoSmithKline reports highlights of third quarter 2012

Novel strategies for lipid management: SOAT inhibitor PRD-017

Aspireo Pharmaceuticals begins phase IIa trial of Somatoprim

Novartis files for approval of QVA-149 in Japan

Cardiovascular benefits demonstrated for SIRT1 activator SRT-2104 in smokers

Bayer presents new protein kinase Akt inhibitors for cancer

Bristol-Myers Squibb patents new lysophospholipid receptor antagonists

Aileron Therapeutics develops new oncology drug candidate

Phase I trial of SMT-C1100 meets endpoints

Takeda Pharmaceutical synthesizes novel ionotropic glutamate receptor agonists

First patient enrolled in phase I/IIa trial of PAT-SM6

FDA advisory committee votes in favor of raxibacumab

Novel gamma-secretase inhibitors disclosed by Merck & Co.

FDA grants priority review to trastuzumab emtansine NDA

MorphoSys and Novartis expand antibody alliance

Pfizer patents novel Trk inhibitors for the treatment of pain

Cadila Pharmaceuticals presents clinical results for CADI-05 in bladder cancer

New nNOS inhibitors presented by Northwestern University

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...